Europe to approve first biosimilars of Neulasta
Executive Summary
Europe’s first biosimilar alternatives to Amgen’s Neulasta (pegfilgrastim) neutropenia treatment are poised to enter the market after the European Medicines Agency (EMA) issued positive opinions for both Accord Healthcare’s Pelgraz and Coherus’ Udenyca 6mg solutions for injection. The European Commission typically decides on whether to convert the opinions into marketing authorisations within 67 days.
You may also be interested in...
Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
HBW US Market News: FTC Returns 'Free Trial' Losses, Old Spice Targets 'Meat Sweats,' More
FTC returns more than $5.4m to more than 100,000 consumers from "free trial" scam;" Hood College names Nutrition Science Program's founding director; Cremer introduces gummy-counting machine; Herbalife renovates LA headquarters; Arby's and Old Spice team up to fight "meat sweats."